Rheumatology International

, Volume 29, Issue 11, pp 1315–1321 | Cite as

Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis

  • Ernst WagnerEmail author
  • M. Skoumal
  • P. M. Bayer
  • K. Klaushofer
Original Paper


The aim of this study was to determine the performance of antibodies against mutated citrullinated vimentin (anti-MCV) in comparison with antibodies to cyclic citrullinated peptides (anti-CCP) in patients with rheumatoid arthritis (RA). Serum levels of anti-MCV and anti-CCP were determined in 193 patients with RA and 332 controls, and sensitivity and specificity were calculated. In a separate analysis of 86 patients, the anti-MCV levels were compared to disease activity. Sensitivity of anti-MCV versus anti-CCP was 71.5 and 69.4%, specificity was 81.3 and 97.6%, respectively. The ROC curves showed higher specificity and an advantage of anti-CCP. In seronegative RA patients the sensitivity of anti-MCV was superior over anti-CCP. Anti-MCV positivities also occurred in systemic lupus erythematosus and Sjoegren’s syndrome. In a subgroup of 86 RA patients we found a significant correlation between anti-MCV and disease activity. Anti-MCV appears to be an important marker for the diagnosis of RA, and correlates also with disease activity.


Anti-mutated citrullinated vimentin Rheumatoid arthritis Inflammatory rheumatic diseases Sensitivity and specificity 



American College of Rheumatology


Anti-citrullinated peptides antibodies


Antibodies against cyclic citrullinated peptide


Antibodies against mutated citrullinated vimentin


Antibodies against Sa-antigen


C-reactive protein


Disease activity score


Enzyme linked immuno sorbent assay


Human leucocyte antigen


Rheumatoid arthritis


Rheumatoid factor


Receiver operating characteristics curve


Systemic lupus erythematosus



D.I. Fabian (Orgentech Company) provided the kits for analysis. Funding for this work was given by Ludwig Boltzmann Cluster (Rheumatology, Balneology and Rehabilitation), Institute of Rheumatology of the Kurstadt Baden, Austria.

Conflict of interest statement

The authors declare that they do not have competing interests.


  1. 1.
    Hassfeld W, Steiner G, Graninger W et al (1999) Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 32:199–203. doi: 10.1093/rheumatology/32.3.199 CrossRefGoogle Scholar
  2. 2.
    Boire G, Cossette P, Brum-Fernandes AJ et al (2005) Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 7:592–603. doi: 10.1186/ar1719 CrossRefGoogle Scholar
  3. 3.
    El-Gabalawy HS, Wilkins JA (2004) Anti-Sa antibodies: prognostic and pathogenic significance to rheumatoid arthritis. Arthritis Res Ther 6:86–89. doi: 10.1186/ar1171 PubMedCrossRefGoogle Scholar
  4. 4.
    Hueber W, Hassfeld W, Smolen JS et al (1999) Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology 38:155–159. doi: 10.1093/rheumatology/38.2.155 PubMedCrossRefGoogle Scholar
  5. 5.
    Lopez-Longo F-J, Rodriguez-Mahou M, Sanchez-Ramon S et al (2006) Anti-cyclic citrullinated peptide versus anti-Sa antibodies in diagnosis of rheumatoid arthritis in an outpatient clinic for connective tissue disease and spondyloarthritis. J Rheumatol 33:1476–1481PubMedGoogle Scholar
  6. 6.
    Vossenaar ER, Després N, Lapointe E et al (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6:R142–R150. doi: 10.1186/ar1149 PubMedCrossRefGoogle Scholar
  7. 7.
    Rantapaa-Dahlquist S, deJong BA, Berglin E et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749. doi: 10.1002/art.11223 CrossRefGoogle Scholar
  8. 8.
    Dejaco C, Klotz W, Larcher H et al (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 8:R119. doi: 10.1186/ar2008 PubMedCrossRefGoogle Scholar
  9. 9.
    Nell VPK, Machold K, Stamm TA et al (2005) Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731–1736. doi: 10.1136/ard.2005.035691 PubMedCrossRefGoogle Scholar
  10. 10.
    Bang H, Egerer K, Gauliard A et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503–2511. doi: 10.1002/art.22817 PubMedCrossRefGoogle Scholar
  11. 11.
    Hartung WE, Schölmerich J, Fredenhagen G et al (2006) Die Bedeutung des mutierten citrullinierten Vimentins (Anti-MCV) für die Differentialdiagnostik der Arthritis. Z Rheumatol 65(Suppl 1):S30. doi: 10.1007/s00393-006-0125-5 Google Scholar
  12. 12.
    Coenen D, Verschueren P, Westhovens R et al (2007) Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 53:498–504. doi: 10.1373/clinchem.2006.078063 PubMedCrossRefGoogle Scholar
  13. 13.
    Soós L, Szekanecz Z, Szabó Z et al (2007) Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 34:1658–1663PubMedGoogle Scholar
  14. 14.
    Rönnelid J, Mullazehi M, Mathsson L (2007) Differential prognostic impact of autoantibodies and inflammation markers in early rheumatoid arthritis. In: Conrad K, Chan EKL, Fritzler MJ, Sack U, Shoenfeld Y, Wiik AS (eds) Autoantigens, Autoantibodies, Autoimmunity, vol 5. Report on the 8th Dresden Symposium on autoantibodies. 12–15 September 2007, pp 389–400Google Scholar
  15. 15.
    Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for rheumatoid arthritis. Arthritis Rheum 31:315–324. doi: 10.1002/art.1780310302 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Ernst Wagner
    • 1
    Email author
  • M. Skoumal
    • 2
  • P. M. Bayer
    • 3
  • K. Klaushofer
    • 4
  1. 1.Institute for Rheumatology of the Kurstadt Baden RSKA Baden of the NOEGKK and Ludwig Boltzmann Cluster Rheumatology, Balneology and RehabilitationForschungsstelle for Epidemiology of Rheumatic DiseasesBadenAustria
  2. 2.Institute for Rheumatology of the Kurstadt Baden 4th Medical Department and Ludwig Boltzmann Institute of Osteology, Hanusch Krankenhaus of WGKKViennaAustria
  3. 3.Central LaboratoryWilhelminen HospitalViennaAustria
  4. 4.4th Medical Department and Ludwig Boltzmann Institute of Osteology, Hanusch Krankenhaus of WGKK and AUVA Trauma Centre MeidlingViennaAustria

Personalised recommendations